Our team

The inventors

Jacques Fantini & Nouara Yahi

The scientific discoveries underlying the creation of AmyPore are based on the work of two internationally recognized university professors, Nouara Yahi (Aix-Marseille University) and Jacques Fantini (Aix-Marseille University and Institut Universitaire de France), who together have more than 300 publications in renowned scientific journals.

Nouara Yahi and Jacques Fantini own the intellectual property of the patent and AmyPore has an exclusive operating license to develop AmyP53 as an anti-Alzheimer's and Parkinson's drug worldwide.

Driss Fantini
A Master 2 Grande Ecole Program graduate from Kedge Business School and also from the University of Aix-Marseille entrepreneurship Pépite-PACA, Driss Fantini created the AmyPore Company in 2018, and was therefore responsible for the H2020 SME Phase 1 AmInnovation program.
Philippe Crespo
General manager
Engineer plus MBA from the University of Artford (USA), Philippe Crespo has extensive experience in international trading and project management. He has developed recognized expertise in the deployment of international networks of companies and joint ventures, on 5 continents, in a high-tech environment and sometimes in complex contractual schemes.
Dr. Henri Chahinian (Ph.D.)
Chairman of the Ethics and Scientific Committee.
Assistant Professor at the University of Aix-Marseille, Dr. Henri Chahinian is an internationally recognized specialist in the biochemistry of lipids and proteins of biological membranes. He has 40 years of experience in basic and applied research.
Dr. Coralie Di Scala (Ph.D.)
Member of the Scientific and Ethics Committee.
Dr. Di Scala obtained his doctoral thesis in 2014 on amyloid pores. She has internationally recognized skills in molecular neuroscience. She is currently leading a neuroscience research team in Helsinki, Finland.
Jacques Fantini (Ph.D.)
Member of the ethics and scientific committee
Professor at the University of Aix-Marseille, member of the Institut Universitaire de France, Jacques Fantini is the author of more than 200 scientific publications (including 4 PNAS articles communicated by two Nobel Prizes and two Lasker Prizes). A globally recognized specialist in molecular modeling, he has developed new concepts of artificial intelligence applied to membrane systems in the context of molecular neurosciences and infectious diseases. He is the co-inventor of the patented AmyP53 molecule for which he holds, with Pr. Nouara Yahi, the intellectual property.
Nouara Yahi (Ph.D.)
Member of the ethics and scientific committee
Professor at the University of Aix-Marseille, Nouara Yahi is the author of more than 100 scientific publications (including 1 Nature and 2 PNAS communicated by a Nobel Prize and a Lasker Prize). Her work on the mechanisms of HIV infection is directly behind the discovery of the common mechanisms of amyloid pore formation and the role of membrane lipids (gangliosides and cholesterol) in this process. Prof. Nouara Yahi is co-inventor of the patented AmyP53 molecule, of which she, along with Prof. Jacques Fantini, holds the intellectual property.
Mohand Sidi Saïd
Strategic advisor
Former Vice-President of Pfizer Inc, of which he was notably one of the operational Presidents. He is currently President of an Endowment Fund, author, lecturer and temporary teacher at Aix PO. He is a fervent defender of access to innovative care for the most disadvantaged in our societies. Author of numerous articles on health models, he has published "The Spirit and the Molecule" 2012, "Help Our Health is in Danger", 2016, "From Djurdjura to Manhattan", 2020. Mohand Sidi Saïd joined the team in 2020 to participate in the development of the AmyP53 solution. A follower of the knowledge economy and AI-artificial intelligence, Mohand Sidi Saïd shares his experience in the pharmaceutical industry and his strategic advice in the health sector.